Perindopril

Generic Name: Perindopril

Brand Names: Aceon, Coversyl, Prestalia, Viacoram

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₃₂N_₂O_₅

CAS Number: 82834-16-0

Unique Ingredient Identifier: Y5GMK36KGY

Background: Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.

Indication: For the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.

Associated Conditions: Cardiovascular Events, Diabetic Nephropathy, Hypertension, Hypertension, Essential Hypertension, Myocardial Infarction, NYHA Class I Congestive heart failure, Stroke, Chronic heart failure with reduced ejection fraction (NYHA Class II), Chronic heart failure with reduced ejection fraction (NYHA Class III)

Associated Therapies: -

Clinical Trials

Timely Recovery After Subclinical Heart Failure

Phase 4

Recruiting

Conditions: Diastolic Dysfunction
Heart Failure

Interventions: Drug: Perindopril

First Posted Date: 2024-04-02

Last Posted Date: 2024-04-02

Lead Sponsor: Academisch Ziekenhuis Maastricht

Target Recruit Count: 130

Registration Number: NCT06341101

Locations: 🇳🇱
AZMaastricht, Maastricht, Limburg, Netherlands

Precision Treatment With Angiotensin Converting Enzyme Inhibitor

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: genotyping and selection of renin-angiotensin system blocker
Drug: Perindopril

First Posted Date: 2022-09-10

Last Posted Date: 2023-01-11

Lead Sponsor: Yonsei University

Target Recruit Count: 77

Registration Number: NCT05535595

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia

Phase 3

Terminated

Conditions: Dyslipidemias
Hypertension

Interventions: Drug: Atorvastatin/Perindopril
Drug: Atorvastatin
Drug: Perindopril

First Posted Date: 2020-10-19

Last Posted Date: 2023-10-18

Lead Sponsor: Institut de Recherches Internationales Servier

Target Recruit Count: 146

Registration Number: NCT04591808

Locations: 🇺🇦
Medical center ''CONSILIUM MEDICAL'', Kyiv, Ukraine
🇺🇦
Private Small-Scale Enterprise Medical Center "Pulse", Vinnytsya, Ukraine
🇷🇺
Saint Petersburg state budgetary institution of healthcare "City policlinic #109", Saint Petersburg, Russian Federation

and more 40 locations

Early Treatment of ARNI on Myocardial Remodeling and Progress

Phase 4

Conditions: Myocardial Infarction

Interventions: Drug: sacubitril/valsartan
Drug: perindopril
Other: Cardiopulmonary Exercise Test
Other: Echocardiogram

First Posted Date: 2020-04-13

Last Posted Date: 2020-04-14

Lead Sponsor: RenJi Hospital

Target Recruit Count: 280

Registration Number: NCT04342351

Locations: 🇨🇳
RenJi Hospital, Shanghai JiaoTong University, School of Medicine, Shanghai, Shanghai, China

Comparative Effects of Perindopril and Zofenopril on Blood Pressure Control and Oxidative Status Blacks Hypertensive Patients.

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Zofenopril, Calcium Salt, (1(R*),2Alpha,4Alpha)-isomer
Drug: Perindopril Arginine

First Posted Date: 2020-02-05

Last Posted Date: 2020-02-05

Lead Sponsor: Yaounde Central Hospital

Target Recruit Count: 24

Registration Number: NCT04254042

Locations: 🇨🇲
Yaounde Central Hospital, Cardiology department, Yaounde, Cameroon

Evaluation of Losartan and Perindopril in Blacks Type 2 Diabetics Patients

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Perindopril Arginine
Drug: Losartan Potassium

First Posted Date: 2020-01-10

Last Posted Date: 2020-01-10

Lead Sponsor: Yaounde Central Hospital

Target Recruit Count: 23

Registration Number: NCT04222686

Locations: 🇨🇲
Yaounde Central Hospital, NAtional Obesity Center, Yaounde, Cameroon

Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.

Phase 4

Completed

Conditions: Hypertension
Hyperuricemia
Menopause

Interventions: Drug: Hydrochlorothiazide
Drug: Perindopril
Drug: Estracomb TTS

First Posted Date: 2019-04-19

Last Posted Date: 2019-04-22

Lead Sponsor: Anna Posadzy-Małaczyńska

Target Recruit Count: 180

Registration Number: NCT03921736

ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension

Phase 2

Active, not recruiting

Conditions: Sedentary Lifestyle
Aging
Hypertension

Interventions: Behavioral: Aerobic exercise
Drug: Perindopril
Drug: Losartan
Drug: HCTZ

First Posted Date: 2017-09-28

Last Posted Date: 2024-05-08

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 213

Registration Number: NCT03295734

Locations: 🇺🇸
UAB Center for Exercise Medicine, Birmingham, Alabama, United States
🇺🇸
Translational Research Institute, Orlando, Florida, United States

Influence of Carboxypeptidase D (CPD) Gene on Body Weight and Fat Mass Reduction by Perindopril in Obese Subjects

Phase 2

Terminated

Conditions: Obesity

Interventions: Drug: Perindopril

First Posted Date: 2016-05-19

Last Posted Date: 2017-08-03

Lead Sponsor: Gene PreDiT

Target Recruit Count: 140

Registration Number: NCT02777489

Locations: 🇵🇹
Unidade de Saúde Familiar Escariz, Arouca, Portugal
🇵🇹
Centro Hospitalar de São João (CHSJ), E.P.E, Porto, Portugal
🇵🇹
Unidade de Cuidados de Saúde Personalizados Carvalhido, Porto, Portugal

and more 10 locations

Perindopril vs Ramipril for Persistence in MAU Reduction Study

Phase 3

Completed

Conditions: Diabetes
Microalbuminuria

Interventions: Drug: perindopril
Drug: ramipril

First Posted Date: 2016-04-06

Last Posted Date: 2016-04-06

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 23

Registration Number: NCT02729441

Locations: 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy